FDA Accepts Merck's Application to Expand ENFLONSIA Use for High-Risk Toddlers

Key Facts

In a move that strengthens the company's position in the specialized vaccine sector, Merck announced that the U.S. FDA has accepted a supplemental Biologics License Application (sBLA) for ENFLONSIA. The application seeks to expand the drug's indication to include children under two years of age who are at increased risk for severe respiratory syncytial virus (RSV) disease during their second season. This represents positive regulatory progress for a core product within the company's pharmaceutical portfolio.

This development comes as market data shows steady performance for the company's stock, with MRK closing at $128.32 as of August 5, 2026. During that trading session, the stock reached a high of $131.07 and a low of $127.56, reflecting investor reaction to the company's operational and regulatory milestones in the healthcare industry.

Investors should watch current support levels near $127.56, the low recorded at the August 5, 2026 close. With no immediate upcoming events in the economic calendar specifically targeting the U.S. pharma sector in the next few days, market focus will remain on any further updates from the FDA regarding the final approval timeline for the vaccine's expanded indication.